FDA OKs Stem Cell Therapy to Reduce Infection Risk

The agency called the approval of omidubicel "an important advance" for patients with blood cancer who are undergoing allogeneic umbilical cord blood stem cell transplants.
FDA Approvals

source https://www.medscape.com/viewarticle/990896?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?